近期论文

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Baseline von Willebrand factor predicts the development of pulmonary artery hypertension in systemic sclerosis. Barnes TC, Gliddon AE, Doré CJ, Maddison P, Moots RJ and the QUINs trial study group. Rheumatology 2012 Sep; 51(9): 1606-9. Neutrophil derived reactive oxygen species in systemic sclerosis. Barnes TC, Anderson ME, Edwards SW, Moots RJ. Rheumatology 2012 Jul; 51(7): 1166-9. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy and fibrosis in systemic sclerosis. Barnes TC, Anderson ME, Moots RJ. Int J Rheumatol 2011: 721608. Epub 2011 Sep 20. Relative α1-antitrypsin deficiency in systemic sclerosis. Barnes TC, Cross A, Anderson ME, Edwards SW, Moots RJ. Rheumatology 2011 Aug; 50(8): 1373-8. Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin-6 trans-signalling: a novel target for systemic sclerosis? Barnes T, Spiller D, Anderson ME, Edwards SW, Moots RJ. Ann Rheum Dis 2011; 70(2): 366-372. Targeting oncostatin M in the treatment of rheumatoid arthritis. Barnes T, Moots RJ. In: New Therapeutic Targets in Rheumatoid Arthritis. (Tak P-P. Ed.) Birkhauser. 2009. Changes underlying the dynamic contrast-enhanced MRI response to treatment in rheumatoid arthritis. Hodgson RJ, Barnes T, Connolly S, Eyes B, Campbell RS, Moots R. Skeletal Radiol. 2008 Mar; 37(3):201-7. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Gliddon AE, Doré CJ, Black CM, McHugh N, Moots R, Denton CP, Herrick A, Barnes T, Camilleri J, Chakravarty K, Emery P, Griffiths B, Hopkinson ND, Hickling P, Lanyon P, Laversuch C, Lawson T, Mallya R, Nisar M, Rhys-Dillon C, Sheeran T, Maddison PJ. Arthritis Rheum. 2007 Nov; 56(11):3837-46. Dynamic contrast enhanced MRI of bone marrow oedema in rheumatoid arthritis. Hodgson R, Grainger A, O'Connor P, Barnes T, Connolly S, Moots R. Ann Rheum Dis. 2008 Feb;67(2):270-2. Pharmacokinetic modeling of dynamic contrast-enhanced MRI of the hand and wrist in rheumatoid arthritis and the response to anti-tumor necrosis factor-alpha therapy. Hodgson RJ, Connolly S, Barnes T, Eyes B, Campbell RS, Moots R. Magn Reson Med. 2007 Sep;58 (3):482-9. Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol. Barnes T, Moots R. Int J Nanomedicine. 2007; 2(1):3-7. Therapeutic targeting of cytokines. Barnes T, Goodacre J, Moots RJ. Cytokine. 2006 Aug; 35(3-4):217-9. Neutrophil apoptosis in rheumatoid arthritis is regulated by local oxygen tensions within joints. Cross A, Barnes T, Bucknall RC, Edwards SW, Moots RJ. J Leukoc Biol. 2006 Sep; 80(3):521-8. Cytokine medicines in clinical practice: current issues. Barnes T, Moots RJ, Goodacre J. Cytokine. 2005 Oct 21; 32(2):62-6. Epub 2005 Sep 26. Second International Conference on Cytokine Medicines. Barnes T, Goodacre J, Moots RJ. Expert Opin Biol Ther. 2005 Sep; 5(9):1255-8. Vitamin D deficiency in a patient with systemic lupus erythematosus. Barnes TC, Bucknall RC. Rheumatology (Oxford). 2004 Mar; 43(3):393-4. Bone turnover in untreated polymyalgia rheumatica. Barnes TC, Daroszewska A, Fraser WD, Bucknall RC. Rheumatology (Oxford). 2004 Apr; 43(4):486-90. A neural influence on the appearance of sodium current in Xenopus embryonic myocytes. Prabhakar E, Barnes T, Spruce AE. Neurosci Lett. 1996 Apr 5; 207(3):203-5.